The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.

Kiyotaka Yoh,Shingo Matsumoto,Kei Kunimasa,Masahiro Kodani,Koichi Nishi,Taku Nakagawa,Shunichi Sugawara,Tomohiro Kato,Jun Sakakibara-Konishi,Yuichiro Hayashi,Koji Tsuta,Noriko Motoi,Genichiro Ishii,Koichi Goto

The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.

2019

Kiyotaka Yoh
Shingo Matsumoto
Kei Kunimasa
Masahiro Kodani
Koichi Nishi
Taku Nakagawa
Shunichi Sugawara
Tomohiro Kato
Jun Sakakibara-Konishi
Yuichiro Hayashi
Koji Tsuta
Noriko Motoi
Genichiro Ishii
Koichi Goto

9046Background: The efficacy of immune checkpoint inhibitors (ICI) and PD-L1 status in patients with advanced non-small cell lung cancer (NSCLC) harboring oncogenic alterations has not been fully i...

Keywords:

PD-L1
Cell
Lung cancer
Immune checkpoint
Biomarker (medicine)
Medicine
Internal medicine
Oncology
in patient
non small cell
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations